Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y- T101, in patients with CD5-expressing leukemia and lymphoma

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2691-2700

  Foss, Francine M ^a,d   Raubitscheck, Andrew ^a   Mulshine, James L ^a   Fleisher, Thomas A ^b   Reynolds, James C ^b   Paik, Chang H ^b   Neumann, Ronald D ^b   Boland, Cynthia ^f   Perentesis, Patricia ^b   Brown, Margaret R ^b   Frincke, James M ^c,e   Lollo, Charles P ^c   Larson, Steven M ^b   Carrasquillo, Jorge A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Hybritech Incorporated   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e Hollis Eden Pharmaceuticals Inc   (United States)

^f Hollis Eden Pharmaceuticals ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; INDIUM 111; MONOCLONAL ANTIBODY T 101; MONOCLONAL ANTIBODY T 101 Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ARTICLE; BIOACCUMULATION; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; LEUKEMIA; LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD5; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE SUBSETS; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0031724899     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Royston, I., Majda, J. A., Baird, S. M., Meserve, B. L., and Griffiths, J. C. Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J. Immunol, 125:725-731, 1980.
2. Carrasquillo, J. A., Bunn, P. A., Jr., Keenan, A. M., Reynolds, J. C., Schroff, R. W., Foon, K. A., Su, M. H., Gazdar, A. F., Mulshine, J. L., Oldham, R. K., et al. Radioimmunodetection of cutaneous T-cell lymphoma with In-111 labeled T101 monoclonal antibody. N. Engl. J. Med., 315: 673-680, 1986.
3. 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J. Clin. Oncol., 5: 562-573, 1987.
4. Zimmer, A. M., Kaplan, E. H., Kazikiewiez, J. M., Goldman-Leikin, R., Gilyon, K. A., Dykewicz, M. S., Spies, W. G., Silverstein, E. A., Spies, S. M., and Rosen, S. T. Pharmacokinetics of I-131 T101 monoclonal antibodies in patients with chronic Lymphocytic leukemia. Antibody Immunoconj. Radiopharm., 1: 291-302, 1988.
5. Dillman, O., Shawler, D. L., Dillman, J. B., and Royston, I. Therapy of chronic lymphocytic leukemia and CTCL with T101 antibody. J. Clin. Oncol., 2: 881, 1984.
6. Carresquillo, J., Kramer, B., Fleisher, T., Perentesis, P., Boland, C., Foss, F., Rotman, M., Reynolds, C., Mulshine, J., Camera, L., Frineke, J., Lollo, C., Neumann, R., Larson, S., and Raubitschek, A. In-111 versus Y-90 biodistribution in patients with hematopoietic malignancies. J. Nucl. Med. 325: 970, 1991.
7. Naruki, Y., Carrasquillo, J., Reynolds, J., Maloney, P., Frincke, J., Neumann, R., and Larson, S. Differential cellular catabollism of In-111, Y-90, and I-125 radiolabeled T101 anti-CD5 monoclonal antibody. Int. J. Rad. Appl. Instrum. Part B, 17: 201-207, 1990.
8. Reynolds, J. C., Del Vecchio, S., Sakahara, H., Lora, M. E., Carrasquillo, J. A., Neumann, R. D., and Larson, S. M. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Rad. Appl. Instrum. Part B, 16: 121-125, 1989.
9. Meares, C. F., Moi, M. K., Diril, H., Kukis, D. L., McCall, M. J., Deshpande, S. V., DeNardo, S. J., Snook, D., and Epenetos, A. A. Macrocyclic chelates of radiometals for diagnosis and therapy., Br. J. Cancer, 62: 21-26, 1990.
10. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
11. Carrasquillo, J. A., Reynolds, J. C., Bunn, P. A., Foon, K. A., Shuke, N., Schroff, R. W., Mulshine, J. L., Perentesis, P., Szymendera, J., Horowitz, M., and Larson, S. M. Pharmacokinetics of In-111 T101 (Anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma. Antibody Immunoconj. Radiopharm., 6: 111-126, 1995.
12. Gibauldi, M. Biopharmaceutics and Clinical Pharmacokinetics, 3rd ed., pp. 72-84. Philadelphia, PA: Lea and Febiger, 1984.
13. Wittes, R. Common toxicity criteria for cancer clinical trials. In: R. Wittes, (ed), Manual of Oncologic Therapeutics, pp. 445-448. Philadelphia, PA: J. B. Lippincott Co., 1991.
14. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
15. Kaminski, M. S., Fig, L. M., Zasadny, K. R., Koral, K. F., DelRosario, R. B., Francis, I. R., Hanson, C. A., Normolle, D. P., Mudgett, E., Liu, C. P., et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol., 10: 1696-1711, 1992.
16. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
17. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., Goldman, C. K., Bamford, R., Zaknoen, S., Roessler, E., Kaslen-Sparks, C., England, R., Litou, H., Johnson, J., Jackson-White, T., Manns, A., Manchard, B., Jinghans, R., and Nelson, D. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86: 4063-4075, 1995.
18. Foss, F., Kuzel, T. Experimental Therapies in Cutaneous T-cell lymphoma. Hematol. Clin. N. Am., 9: 1127-1138, 1995.
19. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M., Pai, L., McMurry, T., Gansow, O., Pastan, I., Paik, C., and Carrasquillo, J. Evaluation of the serum stability and in vivo biodistribution of the 2-(p-isothiocyanatobenzyl)-cyclohexyl-DTPA (CHX-DTPA) and other ligands for Yttrium-labeling of monoclonal antibodies. J. Nucl. Med., 35: 882-889, 1994.
20. Jowsey, J., Rowland, R., and Marshall, J. The deposition of the rare earths in bone. Radiat. Res., 8: 490-501, 1958.
21. Sausville, E. A., Worsham, G. F., Matthews, M. J., Makuch, R. W., Fischmann, A. B., Schechter, G. P., Gazdar, A. F., and Bunn, P. A. Jr. Histologic assessment of lymph nodes in mycosis fungoides/ Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum. Pathol., 16: 1098-1109, 1985.